JACOBSON PHARMA: 2023/2024 Annual Report
Guoyuan Securities: Each overseas business model has its own advantages and disadvantages. Pharmaceutical companies should choose according to their own size.
Leveraging external resources is currently the most mainstream mode for Chinese pharmaceutical companies to expand overseas, which is suitable for companies with limited resources and in need of international experience accumulation, but it also means that the company's voice will be weakened and the relative benefits of sharing will be limited.
Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).
Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.
Hong Kong stock market concept tracking | Heavy policies supporting the development of innovative drugs are introduced! The industry is expected to enter the fast lane of development (with concept stocks).
On July 5th, the State Council's executive meeting discussed and deployed the work related to promoting high-quality development of the digital economy, and approved the Implementation Plan for Supporting the Development of Innovative Drugs throughout the Whole Chain.
Jacobson Pharma's Fiscal Year 2024 Profit, Revenue Rise
Jacobson Pharma will distribute a final dividend of HKD 0.03 per share on October 4th.
Jacobson Pharma (02633) announced that it will distribute a final dividend of HKD 0.03 per share for the year ending March 31, 2024 on October 4, 2024.
Jacobson Pharma released its 2024 annual performance, with a net profit attributable to shareholders of HKD267 million, an increase of 6.34% year-on-year.
Jacobson Pharma (02633) released its annual results for the year ending March 31, 2024, with a revenue of HKD1.468 billion, an increase of 15.79% YoY. The profit attributable to equity holders of the company was HKD267 million, an increase of 6.34% YoY, and the basic earnings per share were 13.9 Hong Kong cents. A final dividend of 3 Hong Kong cents per share is proposed.
Jacobson Pharma (02633.HK) had a continuous business income of approximately 1.468 billion Hong Kong dollars for the year, with a year-on-year increase of approximately 15.8%.
Jacobson Pharma (02633.HK) announced that the revenue from ongoing business operations for the fiscal year ended on March 31, 2024 was approximately HKD 1,467.8 million, an increase of approximately 15.8% compared with the same period in 2023. The net profit for the year was approximately HKD 290.8 million, an increase of approximately 14.4% compared to adjusted net profit for the same period in 2023 (excluding Hong Kong government's one-time job retention plan subsidy), which was approximately HKD 254.1 million. The board of directors recommended a final dividend of HKD 0.03 per share for the year, with a total amount of approximately HKD 60.0.
Jacobson Pharma (02633) will distribute a final dividend of HKD 0.03 per share on October 4.
Jacobson Pharma (02633) announced that it will distribute the interim dividend for the six months ended March 2024 on October 4, 2024.
Express News | Jacobson Pharma Corporation FY Net Income Attributable HKD 267 Million
Express News | Jacobson Pharma Corporation FY Adjusted Ebitda HKD 453.1 Million
Express News | Jacobson Pharma Corporation - Recommends Payment of Final Dividend of HK3.00 Cents per Share
Express News | Jacobson Pharma Corporation FY Revenue HKD 1,467.8 Million
JACOBSON PHARMA: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 MARCH 2024
Jacobson Pharma (02633.HK) plans to hold a board of directors meeting on June 20th to approve the annual performance.
Jacobson Pharma (02633.HK) announced that the Board of Directors will hold a board meeting on Thursday, June 20, 2024 to consider and approve the annual full-year performance as of March 31, 2024 for the Company and its subsidiaries for publication, and to consider recommending the payment of final dividends (if any) and handling other matters.
JACOBSON PHARMA: DATE OF BOARD MEETING
A record high! The total number of clinical trials exceeded 4,000 in 2023
According to the report, in 2023, the total number of clinical trials registered on the drug clinical trial registration and information disclosure platform surpassed 4,000 for the first time, reaching 4,300 (in terms of CTR), the highest total number of registrations in history, an increase of 26.1% over the total number of registrations in 2022.
Zhitong Hong Kong Shareholders' Rights Disclosure | April 16
Disclosure of Hong Kong Stock Shareholders' Rights | April 16
Jacobson Pharma Raises HK$39 Million From Share Placement
Jacossen Pharmaceutical (02633) completed the placement of a total of 66 million shares
Jacochen Pharmaceutical (02633) issued an announcement. All conditions contained in the placement agreement have been met, and the placement has been completed on 20...
No Data